Premium
Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation
Author(s) -
Gazi Emine,
Temiz Ahmet,
Barutcu Ahmet,
Colkesen Yucel
Publication year - 2013
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21106
Subject(s) - atrial fibrillation , medicine , stroke (engine) , discovery and development of direct thrombin inhibitors , rivaroxaban , risk factor , anticoagulant , intensive care medicine , cardiology , warfarin , thrombin , platelet , mechanical engineering , engineering
Clinical Development Phases I‐III Regulatory, Quality, ManufacturingAtrial fibrillation ( AF ) is both a health and a social problem. AF is related to the elevated risk of thromboembolic events with stroke being the most important. It adversely affects life expectancy and quality. The risk of ischemic stroke is increased fivefold in patients with AF . Therapeutic options for lowering the risk of stroke in patients with AF consist of vitamin K antagonists and antiplatelet agents, which have relative risk reductions of approximately 60% and 20%, respectively. Alternative therapeutic options available to reduce the risk of stroke in patients with nonvalvular AF are relatively new. In recent years, new oral anticoagulants have been introduced for this indication. Reversible direct thrombin inhibitors and factor X a inhibitors are new oral anticoagulant agents that have demonstrated efficacy and good safety profiles for preventing stroke and embolic events. The intent of this overview is to review the novel oral anticoagulants recommended for stroke prevention in patients with AF .